GLENMARK.NS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 13:00):

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally...

Stats
Šios dienos apimtis	475 439
Vidutinė apimtis	1.23M
Rinkos kapitalizacija	304.58B
EPS	INR-12.45 ( 2024-02-15 )
Kita pelno data	( INR7.93 ) 2024-05-15
Last Dividend	INR2.50 ( 2023-09-18 )
Next Dividend	INR0 ( N/A )
P/E	-39.84
ATR14	INR1.149 (0.11%)

Tūris Koreliacija

Ilgas: -0.34 (neutral)

Trumpas: -0.37 (neutral)

Signal:(46.547) Neutral

Glenmark Pharmaceuticals Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
AUROPHARMA.NS	0.938
ADORWELD.NS	0.93
ANURAS.NS	0.923
IZMO.NS	0.914
GISOLUTION.NS	0.907
ANMOL.NS	0.905
CAREERP.NS	0.889
KSB.NS	0.884
SETF10GILT.NS	0.879
GTNTEX.NS	0.876

10 Labiausiai neigiamai susiję koreliacijos
KOHINOOR.NS	-0.876
SEYAIND.NS	-0.867
DEEPINDS.NS	-0.855
MERCATOR.NS	-0.849
STARTECK.NS	-0.835
ALLCARGO.NS	-0.808
ORTINLAB.NS	-0.807
KBCGLOBAL.NS	-0.803
SWANENERGY.NS	-0.803

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Glenmark Pharmaceuticals Koreliacija - Valiuta/Žaliavos

-0.06
( neutral )

-0.25
( neutral )

0.13
( neutral )

-0.01
( neutral )

0.21
( neutral )

-0.14
( neutral )

Glenmark Pharmaceuticals Finansinės ataskaitos

Annual	2022
Pajamos:	INR127.25B
Bruto pelnas:	INR81.88B (64.35 %)
EPS:	INR10.53

FY	2022
Pajamos:	INR127.25B
Bruto pelnas:	INR81.88B (64.35 %)
EPS:	INR10.53

FY	2022
Pajamos:	INR121.74B
Bruto pelnas:	INR77.14B (63.37 %)
EPS:	INR33.37

FY	2021
Pajamos:	INR108.06B
Bruto pelnas:	INR70.62B (65.35 %)
EPS:	INR34.38

Financial Reports:

No articles found.

Glenmark Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR2.50 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR2.50 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Glenmark Pharmaceuticals Dividend Information - Dividend Junior

Dividend Sustainability Score: 0.0208 - low (50.00%) | Divividend Growth Potential Score: 2.81 - Decrease likely (43.80%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR0.600	2002-09-12
Last Dividend	INR2.50	2023-09-18
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	22	--
Total Paid Out	INR30.90	--
Avg. Dividend % Per Year	0.37%	--
Score	1.29	--
Div. Sustainability Score	0.0208
Div.Growth Potential Score	2.81
Div. Directional Score	1.416	--

Next Divdend (Est)
(2024-07-01)

INR2.59 Estimate 3.12 %

Dividend Stability

0.25 Very Poor

Dividend Score

1.29

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2002	INR0	0.00%
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR2.00	0.38%
2019	INR2.00	0.29%
2020	INR2.50	0.72%
2021	INR2.50	0.50%
2022	INR2.50	0.48%
2023	INR2.50	0.59%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
RBLBANK.NS	Dividend Junior	2023-08-18	Sporadic	8	0.25%
KOVAI.NS	Dividend Junior	2023-08-10	Annually	4	0.17%
EXIDEIND.NS	Dividend Junior	2023-08-01	Annually	22	0.76%
AMIORG.NS	Dividend Junior	2023-09-18	Annually	3	0.15%
TALBROAUTO.NS	Dividend Junior	2023-09-15	Annually	18	0.48%
NGIL.NS	No Dividend Player	2023-09-21	Annually	4	0.08%
IGPL.NS	Dividend Junior	2023-08-17	Sporadic	18	1.12%
CHEMFAB.NS	Dividend Junior	2023-08-22	Sporadic	7	0.32%
SAKSOFT.NS	Dividend Junior	2023-08-07	Semi-Annually	20	0.56%
LUMAXIND.NS	Dividend Junior	2023-08-10	Annually	23	1.26%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.0581	1.500	-1.161	-1.742	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	-0.0742	1.500	-1.935	-2.90	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	1.901	1.000	-0.407	-0.407	[3 - 30]
operatingCashFlowPerShareTTM	31.65	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	31.65	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.621	1.000	2.99	2.99	[0.2 - 0.8]
operatingProfitMarginTTM	0.0740	1.000	-0.520	-0.520	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				0.0208

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-42.79	1.000	-4.42	0	[1 - 100]
returnOnEquityTTM	-0.0742	2.50	-1.244	-2.90	[0.1 - 1.5]
freeCashFlowPerShareTTM	31.65	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.232	1.500	4.21	0	[0 - 0.4]
operatingCashFlowPerShareTTM	31.65	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.625	1.500	9.17	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0729	1.000	-0.678	0	[0.1 - 0.5]
Total Score				2.81

Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody, which is in Phase 2b clinical trial for the treatment of atopic dermatitis; ISB 1302, a HER2 X CD3 beat bispecific antibody that is in Phase 1/2 clinical trial for the treatment of metastatic HER2-positive breast cancer; and ISB 1342, a CD38 X CD3 beat bispecific antibody, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma. The company's pre-clinical stage product pipeline comprises ISB 880 for the treatment of anti-inflammatory therapy; ISB 1908 and ISB 1909 T-cell engagers for the treatment of oncology; ISB 1442, an innate immune engager for the treatment of oncology; and GRC 39815, an inhibitor of the retinoid-related orphan receptor gamma for the treatment of chronic obstructive pulmonary disorder. It also offers Ryaltris nasal spray for allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.